Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming Marc MacSharry .
Filed returns
16
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 85 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Transport | Impact of Covid-19 on car rental industry and the Irish Tourism Sector as a whole (Legislation) | 16 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland and the role of sustainable mobility solutions in climate action solutions. (Legislation) | 6 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | The impact of COVID-19 on the tourism sector in Ireland, and the specific impact it is having the Irish car rental industry (Legislation) | 20 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 8 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland and the role of sustainable mobility solutions in climate action solutions. (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 18 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 11 | 68.8% | |
| Transport | 5 | 31.2% |